Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma

Annals of the Rheumatic Diseases

Volumn 75, Issue 4, 2016, Pages 780-783

  Nocturne, Gaetane ^a   Tarn, Jessica ^b   Boudaoud, Saida ^a   Locke, James ^b   Miceli Richard, Corinne ^a,c   Hachulla, Eric ^d   Dubost, Jean Jacques ^e   Bowman, Simon ^f   Gottenberg, Jacques Eric ^g   Criswell, Lindsey A ^h   Lessard, Christopher J ⁱ   Sivils, Kathy L ⁱ   Carapito, Raphael ^g,j   Bahram, Siamak ^g,j   Seror, Raphaèle ^a   Ng, Wan Fai ^b   Mariette, Xavier ^c  

^a INSERM   (France)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c BICÊTRE HOSPITAL   (France)

^d Service de médecine nucléaire HÔpital Huriez   (France)

^e Hôpital Universitaire   (France)

^f UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^j UNIVERSITÉ DE STRASBOURG   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; B CELL LYMPHOMA; CASE CONTROL STUDY; CONTROLLED STUDY; EUROPEAN; FISHER EXACT TEST; FRANCE; FRENCHMAN; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MISSENSE MUTATION; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; PRIMARY SJOEGREN SYNDROME ASSOCIATED LYMPHOMA; PRIORITY JOURNAL; SJOEGREN SYNDROME; SOMATIC MUTATION; TNFAIP3 GENE; UNITED KINGDOM; CAUCASIAN; COHORT ANALYSIS; COMPLICATION; GENETICS; GERMLINE MUTATION; META ANALYSIS; MULTIVARIATE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TUMOR; STATISTICAL MODEL;

DNA BINDING PROTEIN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3;

CASE-CONTROL STUDIES; COHORT STUDIES; DNA-BINDING PROTEINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FRANCE; GERM-LINE MUTATION; HODGKIN DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOGISTIC MODELS; LYMPHOMA; LYMPHOMA, B-CELL; MULTIVARIATE ANALYSIS; MYCOSIS FUNGOIDES; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SJOGREN'S SYNDROME; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR ALPHA-INDUCED PROTEIN 3; UNITED KINGDOM;

EID: 84940926601     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207731     Document Type: Article

References (20)

1. Nocturne G, Mariette X. Sjogren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 2015;168:317-27.
2. Brito Zeron P, Kostov B, Solans R, et al. Association between systemic activity and lymphoma in primary Sjogren syndrome: baseline ESSDAI predictors in 921 Spanish patients (GEAS-SS Registry). Ann Rheum Dis 2014;73(Suppl 2):142.
3. Bi Y, Zeng N, Chanudet E, et al. A20 inactivation in ocular adnexal MALT lymphoma. Haematologica 2012;97:926-30.
4. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-16.
5. Novak U, Rinaldi A, Kwee I, et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009;113:4918-21.
6. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009;206:981-9.
7. Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013;72:728-35.
8. Musone SL, Taylor KE, Nititham J, et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun 2011;12:176-82.
9. Nocturne G, Boudaoud S, Miceli-Richard C, et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood 2013;122:4068-76.
10. Du MQ. MALT lymphoma: many roads lead to nuclear factor-kappab activation. Histopathology 2011;58:26-38.
11. Ng WF, Bowman SJ, Griffiths B. United Kingdom Primary Sjogren's Syndrome Registry-a united effort to tackle an orphan rheumatic disease. Rheumatology (Oxford) 2011;50:32-9.
12. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
13. Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. Nat Genet 2013;45:1284-92.
14. Dieude P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009;60:2472-9.
15. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010;26:2190-1.
16. Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008;40:1062-4.
17. Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000;289:2350-4.
18. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjogren's syndrome. Nat Rev Rheumatol 2013;9:544-56.
19. Catrysse L, Vereecke L, Beyaert R, et al. A20 in inflammation and autoimmunity. Trends Immunol 2014;35:22-31.
20. Snow AL, Xiao W, Stinson JR, et al. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. J Exp Med 2012;209:2247-61.